Dr. Trebley’s background in early stage company management and therapeutic development provide the needed expertise to move EmphyMAb assets toward the clinic. Dr. Trebley has a track record for shepherding early-stage companies out of the university setting and into the private sector by obtaining early-stage management and financing, all of which will be of particular importance for EmphyMAb.

Dr. Johnstone directs the early stage development of EmphyMAb’s lead therapeutic for COPD. Dr. Johnstone has over 15 years of experience in early stage biotech companies, where he has served in the executive leadership team, while directing preclinical development of biologics, DNA-based therapies and small molecules. His previous involvement with two early drug development programs has led to Phase I clinical trials.

Dr. Petrache is the lead medical advisor and a contributor to the research direction and clinical insights at EmphyMAb. Dr. Petrache is a physician scientist, board certified in Pulmonary and Critical Care Medicine, and principal investigator of a laboratory that studies mechanisms of lung injury and repair pertinent to cigarette smoke-induced chronic lung disease at Indiana University.

Dr. Clauss maintains a multi-year research program examining the involvement of EMAPII in promoting endothelial cell death. This expertise will be invaluable for guiding the development of this antibody towards clinical application. His research program also involves the study of general mechanisms of endothelial cell death and senescence, with an overall aim of identifying the links between inflammation and angiogenesis.